MATE Improvement Act
- Bill Number
- S. 946
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-03-11: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2026-06-24T19:10:51Z
AI-Generated Summary
Purpose
The Medication Access and Training Expansion Improvement Act (MATE Improvement Act) aims to clarify and expand the training requirements for healthcare professionals who prescribe controlled substances—drugs regulated by the federal government due to their potential for abuse, such as opioids or stimulants. It seeks to make it easier for certain prescribers to meet these requirements by recognizing more training programs and organizations.
Key Provisions
- Amendments to the Controlled Substances Act: The bill modifies Section 303 (21 U.S.C. 823), which governs registration and training for prescribers.
- Redesignates a subsection (the second one labeled as (l)) to (m) for organizational clarity.
- Expands the list of approved organizations whose training programs can satisfy federal requirements, including:
- For physicians and similar providers: Adds the American Academy of Family Physicians, American Podiatric Medical Association, Academy of General Dentistry, American Optometric Association, and Council on Podiatric Medical Education.
- For nurse practitioners and physician assistants: Adds the American Pharmacists Association, Accreditation Council on Pharmacy Education, American Psychiatric Nurses Association, American Academy of Nursing, and American Academy of Family Physicians.
- Includes podiatric medicine (foot and ankle care) and pharmacy education in the types of accredited curricula that qualify for training credits.
- Effective Date: The changes apply retroactively, as if they were enacted on December 29, 2022, allowing prior trainings to count toward compliance.
Significant Changes to Existing Law
- Broadened Recognition of Training: Previously, the law listed fewer organizations and omitted podiatry and pharmacy-specific programs. This bill adds more professional groups and explicitly includes podiatric and pharmacy schools, reducing restrictions on what counts as valid training.
- Retroactive Application: Makes the updates apply from late 2022 onward, potentially validating trainings that might not have qualified before without needing re-certification.
Potential Impacts
- On Government Agencies: The Drug Enforcement Administration (DEA), which enforces the Controlled Substances Act, may see streamlined registration processes for prescribers, reducing administrative burdens and appeals over training validity.
- On Citizens: Patients could benefit from improved access to controlled substances for legitimate medical needs (e.g., pain management), as more prescribers—such as podiatrists, optometrists, and nurse practitioners—can more easily obtain or maintain prescribing authority.
- On International Relations: No direct impacts, as the bill focuses on domestic healthcare regulation.
Main Stakeholders Affected
- Healthcare Professionals: Doctors, podiatrists, dentists, optometrists, nurse practitioners, physician assistants, and pharmacists who prescribe controlled substances; they gain more options for meeting training mandates.
- Professional Organizations: Groups like the American Academy of Family Physicians and American Podiatric Medical Association, whose programs are now explicitly recognized, potentially increasing their influence and membership benefits.
- Patients and the Public: Individuals relying on controlled substances for treatment, who may experience fewer delays in care.
- Federal Regulators: The DEA and Department of Health and Human Services, responsible for oversight and enforcement.
Notable Legal, Constitutional, or Political Implications
- Legal Clarity: Reduces ambiguity in the Controlled Substances Act by explicitly listing more qualifying entities, potentially lowering litigation over training compliance and ensuring consistent enforcement.
- Constitutional Aspects: No direct challenges to constitutional rights; it aligns with Congress's authority to regulate interstate commerce in drugs under the Commerce Clause.
- Political Implications: Bipartisan sponsorship (by Senators Bennet and Collins) suggests broad support for easing healthcare access amid ongoing opioid crisis discussions, without altering core anti-abuse safeguards. The retroactive date could help prescribers avoid penalties for past non-compliance.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Sen. Bennet, Michael F. [D-CO]
Cosponsors (1)
Recent Actions
- 2025-03-11: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-03-11: Introduced in Senate
Bill Versions
- Medication Access and Training Expansion Improvement Act — issued 2025-03-11 — PDF (4 pages)